Simple “closed-circuit” group-specific immunoadsorption system for ABO-incompatible kidney transplants

Balint, Bela; Pavlović, Mirjana; Jevtic, Miodrag; Hrvacević, R; Ignjatović, Ljiljana; Ostojić, Gordana; Mijusković, Z; Blagojevic, R.; Trkuljic, Miroljub

doi:10.1016/j.transci.2006.11.004

Cited by 17 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among 386 transplanted patiets, 316 patients (81.9%) had a living donor and 70 patients (18.1%) deceased donor. Pre-emptive renal transplantation is done in 29 (7.5%), patients and ABO-incompatible kidney transplantation in 21 (5.4%) patients, applying an original method for removal of ABO-isoagglutinins, which is explained elsewhere [9][10][11]…”

Section: Resultsmentioning

confidence: 99%

Graft and patient survival after renal transplantation in the period from 1996-2017 in Military Medical Academy, Belgrade, Serbia

et al. 2022

Self Cite

View full text Add to dashboard Cite

Introduction/Aim: Renal transplantation is the best and preferred way of treating patients with end-stage renal disease, as it offers improved survival and better quality of life in comparison to dialysis. The aim of this study is to show single-center results of the kidney allograft and patient survival during the period from 1996-2017. Methods: This is a retrospective, 22-year cohort study. Variables of interest were graft and patient survival in kidney transplanted patients. Age, gender, creatinine and induction therapy after transplantation were recorded in this group of patients as well. Results: Among 386 transplanted patiets, 316 patients had a living donor and 70 patients deceased donor. Preemptive renal transplantation is done in 29 or 7.5% patients and ABO-incompatible kidney transplantation in 21 or 5.4% patients. One-year, 5-year, 10-year and 20-year overall patient survival after kidney transplantation in the opserved group was 97.7%, 95.3%, 93.8% and 91.7%, respectively. One-year, 5-year, 10-year and 20-year graft survival in the our patinets were 93.8%, 85.5%, 78.5% and 73.3%, respectively. Conclusion: The outcome of graft and patient survival in Military Medical Academy kidney transplantation program are good and in the line with the most eminent world centers.

show abstract

Section: Resultsmentioning

confidence: 99%

Graft and patient survival after renal transplantation in the period from 1996-2017 in Military Medical Academy, Belgrade, Serbia

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Selective therapeutic plasma exchange (TPE) procedure was performed by Spectra-Optia (Terumo BCT; USA), using secondary plasma device protocol and Pentrasorb CRP-adsorber system (Pentracor GmbH; Germany). Antecubital veins were used for vascular access and acid-citrate-dextrose solution (ACD formula A; total volume = 1,026 mL) was utilized as anticoagulant (ACD: whole blood ratio was 1: 10) [7,8]. The volume of processed blood was 15,600 mL.…”

Section: Case Reportmentioning

confidence: 99%

A Promising Innovative Treatment for ST-Elevation Myocardial Infarction: The Use of C-Reactive Protein Selective Apheresis: Case Report

Boljević¹,

Nikolić²,

Rusović³

et al. 2020

Blood Purif

Self Cite

View full text Add to dashboard Cite

Background: In patients with ST-elevation myocardial infarction (STEMI), C-reactive protein (CRP) levels are associated with larger infarct size, transmural extent, and poor function of left ventricle and independently predict 30-day mortality. CRP-apheresis following STEMI showed to be feasible, safe, and has significant beneficial effect both on myocardial infarction size and wall motion. To the best of our knowledge, this is only the second published clinical evaluation of the efficacy and safety of selective CRP-apheresis in the STEMI treatment using Spectra-Optia and Pentrasorb CRP-adsorber systems. Case Report: A 53-year-old female was referred with anterior STEMI. After percutaneous coronary intervention, patient received standard post-STEMI therapy according to current guidelines. Selective therapeutic plasma exchange (TPE) was performed using Spectra-Optia (Terumo BCT; USA) and Pentrasorb CRP-adsorber (Pentracor GmbH; Germany) systems. Antecubital veins were used for vascular access and acid-citrate-dextrose solution (ACD formula A; total volume = 1,026 mL) was utilized as anticoagulant. The volume of processed blood was 15,600 mL. The removed "natural" plasma (total volume = 8,329 mL) was replaced with CRP-depleted autologous plasma (total volume = 8,085 mL). This intensive TPE-treatment was well tolerated, without adverse effects, or complications. The CRP plasma levels were: initial = 4.2 mg/L 6 h after acute myocardial infarction (AMI), pre-apheresis = 16.4 mg/L, and post-apheresis = 4.59 mg/L (CRP-depletion = 72%). There were neither significant changes observed in biochemistry nor any alterations in plasma hemostatic activity investigated before and after CRP-adsorption performed. Conclusion: Early performed CRP-apheresis is a promising innovative therapeutic approach for STEMI treatment that could provide a reduced size of infarction zone-with inferior occurrence of heart failure after AMI. However, precise and complete evaluation of the efficacy and safety of this treatment requires further multicenter randomized and larger clinical studies.

show abstract

“…TAph treatment should be done regularly or always combined with "immunomodulatory" (e.g., immunochemotherapy) and other palliative (drug) therapies. Based upon the criterion of what is the removed blood constituent-with specific "pathogenic factors or substrate"-it is possible to classify the TAph procedures into TPE and therapeutic cytapheresis (TC) [5][6][7][8][9][10][11][12][13][14][15].…”

Section: Apheresis/cytapheresis: a Systematic Overviewmentioning

confidence: 99%

“…TPE is a replacement of the patient's plasma with an adequate substitution fluid (albumin in saline) or with normal (allogeneic) or modified (immunoadsorbed autologous) plasma. The use of "selective" TPE results in reduced risk of side effects (immunomodulation or virus transmission) since "purified" autologous plasma is used as a replacement fluid [11,12].…”

Section: Apheresis/cytapheresis: a Systematic Overviewmentioning

confidence: 99%

Rapid Cytoreduction by Plateletapheresis in the Treatment of Thrombocythemia

Balint¹,

Pavlović²,

Todorović³

2020

Platelets

Self Cite

View full text Add to dashboard Cite

The objective of this chapter is to provide a systematic overview of current knowledge regarding therapeutic apheresis-primarily therapeutic plateletapheresis (TP)-and to summarize evidence-based practical approaches related to cytapheresis treatment of "hyperthrombocytosis" or "extreme thrombocytosis" (ETC). Our results of platelet (Plt) quantitative/qualitative analyses and evaluation of efficacy of apheresis systems/devices-on the basis of Plt removal and in vivo Plt depletion-will be presented. Our preclinical researches confirmed that in Plt concentrates, the initial ratio of discoid shapes was 70%, spherical 20%, and less valuable (dendritic/balloonized) shapes 10%-with morphological score of platelets (MSP = 300-400). After storage, the ratio of discoid and spherical shapes was decreased, while the less valuable ones progressively increased (MSP = 200). Electron microscopy has shown discoid shapes with typical ultrastructural properties. Spherical shapes with reduced electron density and peripheral location of granules/organelles were detected. Also, dendritic shapes with cytoskeletal "rearrangement," membrane system integrity damages, and pseudopodia formations were documented. Our clinical study demonstrated that TP was useful in ETC treatment and should help prevention of "thrombo-hemorrhagic" events-until chemotherapy, antiplatelet drugs, and other medication take effect. During TP treatment, Plt count and morphology/ultrastructure were examined. Plt functions by multiplate analyzer were evaluated. We concluded that intensive TP was an effective, safe, and rapid cytoreductive treatment for ET.

show abstract

Simple “closed-circuit” group-specific immunoadsorption system for ABO-incompatible kidney transplants

Cited by 17 publications

References 22 publications

Graft and patient survival after renal transplantation in the period from 1996-2017 in Military Medical Academy, Belgrade, Serbia

Graft and patient survival after renal transplantation in the period from 1996-2017 in Military Medical Academy, Belgrade, Serbia

A Promising Innovative Treatment for ST-Elevation Myocardial Infarction: The Use of C-Reactive Protein Selective Apheresis: Case Report

Rapid Cytoreduction by Plateletapheresis in the Treatment of Thrombocythemia

Contact Info

Product

Resources

About